New Enterprise Associates 15 L.P. 13D and 13G filings for Inozyme Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 6:08 pm Sale |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
New Enterprise Associates 15 L.P. | 0 0.000% |
-2,437,689 (Position Closed) |
Filing |
| 2022-02-07 1:58 pm Unchanged |
2021-12-31 | 13G | Inozyme Pharma, Inc. INZY |
New Enterprise Associates 15 L.P. | 2,437,689 10.300% |
0 (Unchanged) |
Filing |
| 2021-02-12 1:30 pm Purchase |
2020-12-31 | 13G | Inozyme Pharma, Inc. INZY |
New Enterprise Associates 15 L.P. | 2,437,689 10.400% |
2,437,689 (New Position) |
Filing |